Article

Melatonin agonists and insomnia

Centre for Sleep Research, University of South Australia, GPO Box 2471, Adelaide, SA 5001, Australia.
Expert Review of Neurotherapeutics (Impact Factor: 2.83). 02/2010; 10(2):305-18. DOI: 10.1586/ern.10.1
Source: PubMed

ABSTRACT The ability of melatonin to shift biological rhythms is well known. As a result, melatonin has been used in the treatment of various circadian rhythm sleep disorders, such as advanced and delayed sleep phase disorders, jet lag and shiftwork disorder. The current evidence for melatonin being efficacious in the treatment of primary insomnia is less compelling. The development of agents that are selective for melatonin receptors provides opportunity to further elucidate the actions of melatonin and its receptors and to develop novel treatments for specific types of sleep disorders. The agonists reviewed here - ramelteon, tasimelteon and agomelatine - all appear to be efficacious in the treatment of circadian rhythm sleep disorders and some types of insomnia. However, further studies are required to understand the mechanisms of action, particularly for insomnia. Clinical application of the agonists requires a good understanding of their phase-dependent properties. Long-term effects of melatonin should be evaluated in large-scale, independent randomized controlled trials.

0 Followers
 · 
102 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: What is it that keeps us awake? Our assumption is that we consciously control our daily activities including sleep-wake behavior, as indicated by our need to make use of an alarm clock to wake up in the morning in order to be at work on time. However, when we travel across multiple time zones or do shift work, we realize that our intentionally planned timings to rest and to remain active can interfere with an intrinsic regulation of sleep/wake cycles. This regulation is driven by a small region in the anterior hypothalamus of the brain, termed as the "circadian clock". This clock spontaneously synchronizes with the environmental light-dark cycle, thus enabling all organisms to adapt to and anticipate environmental changes. As a result, the circadian clock actively gates sleep and wakefulness to occur in synchrony with the light-dark cycles. Indeed, our internal clock is our best morning alarm clock, since it shuts off melatonin production and boosts cortisol secretion and heart rate 2-3h prior awakening from Morpheus arms. The main reason most of us still use artificial alarm clocks is that we habitually carry on a sleep depth and/or the sleep-wake timing is not ideally matched with our social/work schedule. This in turn can lead hourglass processes, as indexed by accumulated homeostatic sleep need over time, to strongly oppose the clock. To add to the complexity of our sleep and wakefulness behavior, light levels as well as exogenous melatonin can impinge on the clock, by means of their so-called zeitgeber (synchronizer) role or by acutely promoting sleep or wakefulness. Here we attempt to bring a holistic view on how light, melatonin, and the brain circuitry underlying circadian and homeostatic processes can modulate sleep and in particular alertness, by actively promoting awakening/arousal and sleep at certain times during the 24-h day.
    International Review of Neurobiology 01/2010; 93:57-90. DOI:10.1016/S0074-7742(10)93003-1 · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In elderly patients, insomnia is a common symptom. Insomnia exerts immediate negative effects on quality of life, but also shows a strong bidirectional relationship with serious medical problems. The complex etiology of insomnia in elderly persons warrants meticulous diagnostic assessment. In patients with secondary insomnia, therapy of the causative factors is initiated. Non-pharmacological therapies and behavioral advice constitute the mainstay of symptomatic treatment of insomnia. However, in elderly persons, the efficacy of these measures has not been well established. In general, the therapeutic benefit of hypnotic drugs is small. On the other hand, most substances may have considerable negative side effects. For short-term symptomatic treatment of acute insomnia, hypnotic drugs may be employed. For this indication, Benzodiazepine receptor agonists and prolonged-release Melatonin are drugs of first choice. Generally, prolonged treatment of chronic insomnia in elderly patients is not indicated due to the unclear long-term efficacy and negative side effects of the hypnotic drugs currently available.
    Der Internist 07/2010; 51(7):914-22. · 0.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increasing clinical evidences suggest that melatonin receptor agonists can represent a novel therapeutic approach for the treatment of sleep disturbances and depression. A variety of studies also revealed a role of melatonin and its receptors in different patho-physiological conditions. Due to the multiple effects of this hormone, the design of new agents able to interact selectively with melatonin receptors has become an area of great interest during the last decade. An extensive inspection of patents and scientific literature about MT(1) and MT(2) melatonin receptor agonists reported from 1999 to early 2010. A comprehensive review of structures recently claimed as melatonin receptor agonists and a broad overview of structure-activity relationships for these ligands. After 5 decades of research, the field of melatonin receptor agonists comprises a variety of chemical entities, belonging to structurally different classes. Patents filed since 1999 claim new melatonin receptor agonists, characterized either by improved pharmacokinetic or pharmacodynamic properties, compared to those of melatonin receptor agonists already approved for clinical uses. The results of preclinical studies on animal models show that melatonin receptor agonists can be considered promising agents for the treatment of CNS-related pathologies.
    Expert Opinion on Therapeutic Patents 08/2010; 20(8):1059-77. DOI:10.1517/13543776.2010.496455 · 3.44 Impact Factor
Show more